

Patrick H Lizotte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2159860/publications.pdf>

Version: 2024-02-01

46
papers

5,503
citations

218677

26
h-index

361022

35
g-index

50
all docs

50
docs citations

50
times ranked

11898
citing authors

#	ARTICLE	IF	CITATIONS
1	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	28.9	1,260
2	CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. <i>Cancer Discovery</i> , 2018, 8, 216-233.	9.4	503
3	In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. <i>Nature Nanotechnology</i> , 2016, 11, 295-303.	31.5	392
4	Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. <i>Cancer Discovery</i> , 2018, 8, 196-215.	9.4	392
5	Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12372-12377.	7.1	383
6	Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. <i>Scientific Data</i> , 2014, 1, 140035.	5.3	328
7	False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. <i>Clinical Cancer Research</i> , 2018, 24, 4437-4443.	7.0	321
8	Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. <i>Cancer Cell</i> , 2020, 37, 104-122.e12.	16.8	267
9	Frameshift events predict anti-PD-1/L1 response in head and neck cancer. <i>JCI Insight</i> , 2018, 3, .	5.0	190
10	SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer. <i>Cancer Cell</i> , 2013, 24, 738-750.	16.8	135
11	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 852-867.	9.4	132
12	Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. <i>JCI Insight</i> , 2016, 1, e89014.	5.0	110
13	Immune-Mediated Regression of Established B16F10 Melanoma by Intratumoral Injection of Attenuated <i>Toxoplasma gondii</i> Protects against Rechallenge. <i>Journal of Immunology</i> , 2013, 190, 469-478.	0.8	98
14	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. <i>Cancer Discovery</i> , 2021, 11, 1952-1969.	9.4	87
15	Avirulent <i>Toxoplasma gondii</i> Generates Therapeutic Antitumor Immunity by Reversing Immunosuppression in the Ovarian Cancer Microenvironment. <i>Cancer Research</i> , 2013, 73, 3842-3851.	0.9	86
16	Attenuated <i>Listeria monocytogenes</i> reprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis. <i>Onc Immunology</i> , 2014, 3, e28926.	4.6	66
17	Cytotoxic T Cells in PD-L1 Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. <i>Cancer Immunology Research</i> , 2016, 4, 1038-1048.	3.4	62
18	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. <i>Cancer Immunology Research</i> , 2018, 6, 1511-1523.	3.4	59

#	ARTICLE	IF	CITATIONS
19	Acute pharmacological degradation of Helios destabilizes regulatory T cells. <i>Nature Chemical Biology</i> , 2021, 17, 711-717.	8.0	52
20	TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. <i>JCI Insight</i> , 2018, 3, .	5.0	49
21	Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2022, 28, 468-478.	7.0	45
22	STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	44
23	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 67, 61-69.	1.5	42
24	Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 3431-3442.	7.0	41
25	Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	35
26	Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. <i>Scientific Reports</i> , 2016, 6, 31745.	3.3	22
27	Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. <i>Frontiers in Oncology</i> , 2021, 11, 696512.	2.8	22
28	Activation of Tumor-Cell STING Primes NK-Cell Therapy. <i>Cancer Immunology Research</i> , 2022, 10, 947-961.	3.4	22
29	Stimulating antitumor immunity with nanoparticles. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2014, 6, 496-505.	6.1	21
30	Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2017, 35, 8555-8555.	1.6	10
31	Phase 2 study of tremelimumab plus durvalumab for previously-treated malignant pleural mesothelioma (MPM).. <i>Journal of Clinical Oncology</i> , 2019, 37, 8549-8549.	1.6	9
32	Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6053-6053.	1.6	7
33	Abstract A132: Multi-parametric profiling of non-small cell lung cancers reveals distinct immunophenotypes. , 2016, , .		7
34	Abstract 4935: High-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of CTL antigen-specific tumor cell killing. , 2018, , .		3
35	Abstract 5543: TAK1 deficiency in tumor cells enhances sensitivity to CTL-mediated killing via TNF- α . <i>Cancer Research</i> , 2020, 80, 5543-5543.	0.9	2
36	Abstract LB-218: Validation of a novel microfluidic device for screening of immune checkpoint inhibitors using 3D organotypic tumor spheroids. <i>Cancer Research</i> , 2017, 77, LB-218-LB-218.	0.9	1

#	ARTICLE	IF	CITATIONS
37	Abstract B21: Immune-based treatment of ovarian cancer in a mouse model with attenuated <i>Toxoplasma gondii</i> . , 2013, , .		0
38	Abstract A36: Treatment of established dermal murine B16F10 melanoma with an attenuated <i>Toxoplasma gondii</i> eliminates the treated tumor and stimulates systemic antitumor immunity.. , 2013, , .		0
39	Abstract A68: Local tumor treatments to simulate systemic antitumor immune responses. , 2015, , .		0
40	Abstract A140: Viral-like nanoparticles for tumor immunotherapy by in situ vaccination mediate potent antitumor immunity. , 2016, , .		0
41	Abstract 3682: Synergistic immunostimulatory effects and therapeutic benefit of combined histone deacetylase and bromodomain inhibition in non-small cell lung cancer. , 2017, , .		0
42	Abstract 1686: TSC2 enhances antitumor immunity and potentiates PD-1 and CTLA-4 blockade. , 2018, , .		0
43	Abstract 1483: Ex vivo single cell RNA-sequencing of tumor derived organotypic spheroids identifies a unique mesenchymal resistance program to PD-1 blockade. , 2019, , .		0
44	Abstract PR06: Dissecting mechanisms of replication fork stabilization in patient-derived high-grade serous organoid cultures and their impact on therapeutic sensitivity and the immune-tumor interaction. , 2020, , .		0
45	248â€¦Immuno-therapy persister cells uncovered by dynamic single-cell RNA-sequencing. , 2020, , .		0
46	Abstract 368A: Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids. , 2019, , .		0